Any current/future new fundraising through debt or equity?

The company currently has a net debt of about Rs. 70 crore for FY25. With ongoing and planned capacity expansions, the net debt is expected to approximately double by FY26. The average cost of debt is around 8%. No specific mention of any new fundraising through debt or equity was made in the call. The company appears focused on utilizing internal accruals and existing credit for capacity expansions. Balance sheet is described as healthy with strong liquidity and comfortable leverage levels. No explicit plans disclosed for equity fundraising in the near future. Management is concentrating on d

Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26. Additional CAPEX of Rs. 192 crore approved for phased expansions at subsidiaries Unitop Chemicals, Tristar Intermediates (Rs. 97 crore), and Rossari Biotech (Rs. 95 crore), to be commissioned by Q4 FY26. New expansions emphasize non-Ethylene Oxide (EO) products, backward integration including Esters and Monomers, and new chemistries in the Mellitic space. Investments include scaling up biosurfactant production with a large fermenter addition. R&D expansion underway, including a new center in

Future growth expectations in sales/revenue/volumes?

Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4). HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6). Consumer and Institutional businesses grew 67% YoY to Rs. 299 crore in FY25 and expected to scale meaningfully in coming years, aiming for profitability by FY27 (Pages 4, 13). New CAP

Future growth expectations in earnings/operating earnings/profits/EPS?

Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari). FY27 anticipated as a strong year with CAPEX projects coming online and EO supply issues likely resolved (Ketan Sablok). Mid-teens topline growth expected on an annualized basis, driven by product and market expansion (company outlook). Adjusted core business EBITDA margin maintained around 14.5%-15%, with overall company margin around 13%-13.5% as consumer business grows (Ketan Sablok). Current cost expansions envisaged to peak, leading to margi

IN US

Sale is live|00:00:00left today

Rossari Biotech LtdQ1 FY25Chemicals & Petrochemicals

Rossari Biotech Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 18.8Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6).
→Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4).
→HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6).
→Consumer and Institutional businesses grew 67% YoY to Rs. 299 crore in FY25 and expected to scale meaningfully in coming years, aiming for profitability by FY27 (Pages 4, 13).
→New CAPEX of Rs. 192 crore planned for phased commissioning by Q4 FY26 to enhance production and support sustainable scalable growth (Pages 3-5).
→Expectation of better topline growth and improved EBITDA margins as EO availability issues resolve and new capacities come online by FY27 (Pages 10, 12-13).

Margin guidance

Category 3

→Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).
→FY27 anticipated as a strong year with CAPEX projects coming online and EO supply issues likely resolved (Ketan Sablok).
→Mid-teens topline growth expected on an annualized basis, driven by product and market expansion (company outlook).
→Adjusted core business EBITDA margin maintained around 14.5%-15%, with overall company margin around 13%-13.5% as consumer business grows (Ketan Sablok).
→Current cost expansions envisaged to peak, leading to margin improvement from FY26 onwards (Ketan Sablok).
→New CAPEX including backward integration aimed to drive revenue and margin growth with asset turns in the 2x-3x range (Sunil Chari).
→Institutional and B2C businesses scaled by 67% YoY, adding nearly Rs. 300 crore revenue in FY25, expected to enhance long-term shareholder value.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company currently has a net debt of about Rs. 70 crore for FY25.
→With ongoing and planned capacity expansions, the net debt is expected to approximately double by FY26.
→The average cost of debt is around 8%.
→No specific mention of any new fundraising through debt or equity was made in the call.
→The company appears focused on utilizing internal accruals and existing credit for capacity expansions.
→Balance sheet is described as healthy with strong liquidity and comfortable leverage levels.
→No explicit plans disclosed for equity fundraising in the near future.
→Management is concentrating on disciplined execution of growth initiatives and operational improvements rather than immediate fundraising.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders for Rossari Biotech Limited. However, relevant insights include: - The company completed expansions expected to be commissioned by Q2 and Q4 FY26, aimed at supporting growth and enhancing supply reliability. - Demand remains strong globally with exports growing by 27%, presence in over 70 countries. - The company is cautious with Bangladesh customers due to currency issues but is exploring other geographies like Southeast Asia, Egypt, and Turkey to grow textile exports. - The Institutional and B2C business have scaled meaningfully, delivering 67% YoY growth and about Rs. 300 crore revenue in FY25, indicating strong order momentum in these segments. - Overall, growth initiatives and new product rollouts suggest a healthy demand pipeline supporting mid-teens revenue growth guidance. No direct figure or specific order book size was disclosed in the call.

Capex plans

Yes

→Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
→Additional CAPEX of Rs. 192 crore approved for phased expansions at subsidiaries Unitop Chemicals, Tristar Intermediates (Rs. 97 crore), and Rossari Biotech (Rs. 95 crore), to be commissioned by Q4 FY26.
→New expansions emphasize non-Ethylene Oxide (EO) products, backward integration including Esters and Monomers, and new chemistries in the Mellitic space.
→Investments include scaling up biosurfactant production with a large fermenter addition.
→R&D expansion underway, including a new center in Mumbai and increased staffing for innovation and future product development.
→Aim to enhance production capabilities, supply reliability, operational efficiency, and support scalable, sustainable growth.
→Estimated asset turns for new CAPEX expected around 2x to 3x.
→Rossari Biotech currently cash-positive with zero term loan/CC status; Unitop planning ~Rs. 95 crore expansion.

How does Rossari Biotech Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Rossari Biotech Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Rossari Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio